Northern Trust’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $35.7M | Buy |
1,389,765
+79,109
| +6% | +$1.63M | ﹤0.01% | 1430 |
|
|
2026
Q1 | $25.2M | Buy |
1,310,656
+110,912
| +9% | +$2.21M | ﹤0.01% | 1529 |
|
|
2025
Q4 | $19.8M | Sell |
1,199,744
-34,435
| -3% | -$581K | ﹤0.01% | 1656 |
|
|
2025
Q3 | $17.9M | Buy |
1,234,179
+32,470
| +3% | +$467K | ﹤0.01% | 1760 |
|
|
2025
Q2 | $16.8M | Buy |
1,201,709
+69,536
| +6% | +$979K | ﹤0.01% | 1753 |
|
|
2025
Q1 | $15.4M | Sell |
1,132,173
-69,345
| -6% | -$1.33M | ﹤0.01% | 1786 |
|
|
2024
Q4 | $24.5M | Buy |
1,201,518
+115,876
| +11% | +$2.97M | ﹤0.01% | 1570 |
|
|
2024
Q3 | $31.6M | Buy |
1,085,642
+2,683
| +0.2% | +$66.5K | 0.01% | 1331 |
|
|
2024
Q2 | $25.1M | Sell |
1,082,959
-5,554
| -0.5% | -$107K | ﹤0.01% | 1414 |
|
|
2024
Q1 | $22.3M | Sell |
1,088,513
-13,166
| -1% | -$247K | ﹤0.01% | 1516 |
|
|
2023
Q4 | $23.6M | Sell |
1,101,679
-15,063
| -1% | -$298K | ﹤0.01% | 1495 |
|
|
2023
Q3 | $23M | Buy |
1,116,742
+27,044
| +2% | +$686K | ﹤0.01% | 1449 |
|
|
2023
Q2 | $32.2M | Buy |
1,089,698
+71,694
| +7% | +$2.02M | 0.01% | 1258 |
|
|
2023
Q1 | $23.5M | Buy |
1,018,004
+33,813
| +3% | +$931K | ﹤0.01% | 1455 |
|
|
2022
Q4 | $27.4M | Buy |
984,191
+94,223
| +11% | +$2.8M | 0.01% | 1332 |
|
|
2022
Q3 | $27.3M | Sell |
889,968
-650
| -0.1% | -$21.1K | 0.01% | 1254 |
|
|
2022
Q2 | $26.2M | Sell |
890,618
-15,610
| -2% | -$409K | 0.01% | 1351 |
|
|
2022
Q1 | $29.2M | Sell |
906,228
-52,861
| -6% | -$1.82M | 0.01% | 1407 |
|
|
2021
Q4 | $42.8M | Buy |
959,089
+7,364
| +0.8% | +$349K | 0.01% | 1220 |
|
|
2021
Q3 | $48M | Sell |
951,725
-27,333
| -3% | -$1.54M | 0.01% | 1104 |
|
|
2021
Q2 | $76.8M | Buy |
979,058
+225,424
| +30% | +$13.9M | 0.01% | 819 |
|
|
2021
Q1 | $43M | Sell |
753,634
-24,111
| -3% | -$1.61M | 0.01% | 1236 |
|
|
2020
Q4 | $65.1M | Sell |
777,745
-11,273
| -1% | -$681K | 0.01% | 888 |
|
|
2020
Q3 | $28.3M | Sell |
789,018
-43,242
| -5% | -$1.3M | 0.01% | 1347 |
|
|
2020
Q2 | $20.1M | Buy |
832,260
+134,061
| +19% | +$3.15M | ﹤0.01% | 1618 |
|
|
2020
Q1 | $12.2M | Buy |
698,199
+63,187
| +10% | +$1.32M | ﹤0.01% | 1749 |
|
|
2019
Q4 | $11.1M | Sell |
635,012
-19,439
| -3% | -$324K | ﹤0.01% | 2113 |
|
|
2019
Q3 | $10M | Buy |
654,451
+34,401
| +6% | +$657K | ﹤0.01% | 2138 |
|
|
2019
Q2 | $12.9M | Buy |
620,050
+6,063
| +1% | +$136K | ﹤0.01% | 1988 |
|
|
2019
Q1 | $14.3M | Buy |
613,987
+23
| +0% | +$481 | ﹤0.01% | 1914 |
|
|
2018
Q4 | $12.7M | Buy |
613,964
+14,105
| +2% | +$256K | ﹤0.01% | 1910 |
|
|
2018
Q3 | $13M | Buy |
599,859
+412,925
| +221% | +$6.83M | ﹤0.01% | 2090 |
|
|
2018
Q2 | $2.85M | Buy |
186,934
+18,885
| +11% | +$356K | ﹤0.01% | 3009 |
|
|
2018
Q1 | $3.31M | Buy |
+168,049
| New | +$3.45M | ﹤0.01% | 2829 |
|
Other funds holding DNLI
Northern Trust's DNLI Position: Q2 2026 in Review
Northern Trust increased its Denali Therapeutics (DNLI) stake by 6% in Q2 2026, buying an estimated $1.63M and bringing the position to 1,389,765 shares worth $35.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1430.
Northern Trust first reported a position in DNLI in Q1 2018 and has held it in 34 quarters since. The position peaked at $76.8M in Q2 2021. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.
- Northern Trust held 1,389,765 shares of Denali Therapeutics worth $35.7M as of Q2 2026.
- Northern Trust bought 79,109 Denali Therapeutics shares in Q2 2026, an estimated $1.63M.
- Denali Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #1430 holding.
- Northern Trust first reported a position in Denali Therapeutics in Q1 2018 and has held it in 34 quarters since.
- Northern Trust's Denali Therapeutics position peaked at $76.8M in Q2 2021.
- 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.
Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.